Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-11-23

Clinical Trial Update: A Study of Galcanezumab (LY2951742) in Participants With Migraine Headache [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for galcanezumab (LY2951742) in participants with migraine headache; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Galcanezumab (galcanezumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Migraine Headache | Phase 2 | Status: COMPLETED | Results posted: 2018-11-23